Clinical trials in BioPharma
A recent study revealed that biotechnology companies or universities discovered 42 percent of all innovative drugs approved by the US Food and Drug Administration (FDA) between 1998 and 2007.
Clinical trials and stratified medicine—maximising patent exclusivity
The traditional business model for a new drug relies on a substantial period of market exclusivity to recoup extensive research and development costs.
Traditional medicine patents lead to enhanced drug discovery from natural products
Natural products have been used to relieve a variety of diseases and conditions for millennia.
US Patent Law changes appear imminent
US patent reform looks like it may finally be coming. John Pegram and Mark Ellinger explain the proposed changes.
Patenting genes and diagnostics
As biotechnology patents continue to grow in importance, uncertainty remains on both sides of the Atlantic as to exactly what is patentable. Simon O’Brien and David Gass take a look.
Attacking the validity of selection patents
The Canadian Federal Court of Appeal recently considered whether ‘invalid selection’ can be an independent ground for invalidating selection patents. Katie Wang looks at the implications.
The role of the function of DNA sequence before and after grant
Recent European decisions have provided much to think about for practitioners concerned with DNA sequences. Caroline Pallard and Bart Swinkels investigate.
The Brazilian pharmaceutical sector: a year in review
Practitioners can take heart from recent developments in the Brazilian courts, say Otto Licks and Anderson Nascimento.
Patentability of dosage regimens in Europe
First instance courts in France have adopted controversial interpretations of an important Enlarged Board of Appeal decision, says Stéphane Agasse.
A revolution: biotech patents in India
It has taken a long time for India to develop a productive environment for biotechnology. But recent developments look to have put it on the right track. Archana Shanker explains.
